Europska Unija - hrvatski - EMA (European Medicines Agency)

aimmune therapeutics ireland limited - defatted powder of arachis hypogaea l., semen (peanuts) - peanut hypersensitivity - allergens - palforzia is indicated for the treatment of patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy. palforzia may be continued in patients 18 years of age and older. palforzia should be used in conjunction with a peanut-avoidant diet.

Europska Unija - hrvatski - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - pegfilgrastim - neutropenija - Иммуностимуляторы, , колониестимулирующие faktori - smanjenje duljine trajanja neutropenije i incidencije febrilne neutropenije u odraslih bolesnika liječenih citotoksičnom kemoterapijom zbog zloćudne bolesti (uz iznimku kronične mijeloične leukemije i mijelodisplastičnog sindroma).

Europska Unija - hrvatski - EMA (European Medicines Agency)

bayer ag - radium (223ra) dichloride - prostatske neoplazme - terapeutski radiofarmaceutski pripravci - xofigo je indiciran za liječenje odraslih osoba s karcinomom prostate otpornih na kastriranje, simptomatskim koštanim metastazama i bez poznatih visceralnih metastaza.

Europska Unija - hrvatski - EMA (European Medicines Agency)

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - denga - cjepiva - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 i 4. korištenje dengvaxia moraju biti u skladu sa službenim preporukama.

Europska Unija - hrvatski - EMA (European Medicines Agency)

roche registration gmbh - pertuzumab, trastuzumab - neoplazme dojki - antineoplastična sredstva - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.

Europska Unija - hrvatski - EMA (European Medicines Agency)

janssen-cilag international n.v.    - ponesimod - multipla skleroza, Рецидивно-Ремиттирующее - imunosupresivi - ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.

Europska Unija - hrvatski - EMA (European Medicines Agency)

gilead sciences ireland uc - sacituzumab govitecan - breast neoplasms; triple negative breast neoplasms - antineoplastična sredstva - trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mtnbc) who have received two or more prior systemic therapies, including at least one of them for advanced disease.

Europska Unija - hrvatski - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - karcinom, ne-malih stanica pluća - antineoplastična sredstva - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - belimumab - lupus erythematosus, sistemski - imunosupresivi - benlysta navodi kao dopuna terapije kod pacijenata u dobi od 5 i više godina uz aktivnu, pozitivnu аутоантитела sistemski eritemski lupus (sle) s visokim stupnjem aktivnosti bolesti (e. pozitivna anti-ova dnk i niska razina komplementa), bez obzira na standardnu terapiju. benlysta is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis.

Europska Unija - hrvatski - EMA (European Medicines Agency)

pfizer europe ma eeig - bosutinib (kao monohidrat) - leukemija, mieloid - antineoplastic agents, protein kinase inhibitors - bosulif indiciran za liječenje odraslih bolesnika s prvi put prijavljene kronične faze (cp) kromosoma-pozitivnim philadelphia kronične миелогенной leukemije (ph+ kml). srijeda, ubrzana faza (ap), i бластном (bp) ph+ kml, prethodno liječenih jedan ili više inhibitora тирозинкиназы(s) [тки(e)] i za koga imatinib, nilotinib i dasatinib ne uzeti u obzir odgovarajuće mogućnosti liječenja .